Insightful discoveries
Our technologies analyse drug structures, pharmacological drug data, drug side effects and associated disease phenotypes to discover novel and hidden connections between targets, drugs and diseases.
In just five years, we’ve discovered and delivered several new treatments towards the clinic. We develop partnerships to license some of these treatments out and to license promising, clinic-ready treatments in.
Learn morePartner with us to access our AI technology to discover novel rare disease treatments.
Our AI platform discovers combinations that enhance the monotherapies developed by our partners and academic labs.
To get therapies to patients quicker, we both in-licence and out-license safe clinic-ready and clinically validated assets.
We work with our partners to combine their clinical development expertise with our technology and rare disease assets.
Our technologies analyse drug structures, pharmacological drug data, drug side effects and associated disease phenotypes to discover novel and hidden connections between targets, drugs and diseases.
Rather than approaching the biology of a rare disease with a predetermined target in mind, our technologies use gene expression data to connect drugs and diseases without prior assumptions.
Our technologies present the connections they discover in the form of a knowledge graph. The results are also prioritised, which helps our pharmacologists speed up the interpretation and validation process.